

Imfinzi® (durvalumab) (Intravenous)

-E-

Document Number: EOCCO-0490

Last Review Date: 01/04/2024

Date of Origin: 08/05/2019

Dates Reviewed: 08/2019, 10/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 07/2021, 10/2021, 01/2022, 05/2022, 07/2022, 10/2022, 01/2023, 04/2023, 07/2023, 10/2023, 01/2024

I. Length of Authorization ^{Δ 1}

Coverage will be provided for 6 months and may be renewed (unless otherwise specified).

- Gastric Cancer, Esophageal Cancer and Esophagogastric Junction Cancers: Coverage will be provided for 3 doses.
- Non-Small Cell Lung Cancer (NSCLC) (single-agent use as consolidation therapy): Coverage will be provided for 6 months and may be renewed up to a maximum of 12 months of therapy.*

**Note: The maximum number of doses is dependent on the dosing frequency and duration of therapy. Refer to Section V for exact dosage.*

Dosing Frequency	Maximum length of therapy	Maximum number of doses
2 weeks	1 year	26 doses
4 weeks	1 year	13 doses

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Imfinzi 120 mg/2.4 mL single-dose vial: 4 vials per 14 days
- Imfinzi 500 mg /10 mL single-dose vial: 2 vials per 14 days

B. Max Units (per dose and over time) [HCPCS Unit]:

- NSCLC:
 - 112 billable units (1,120 mg) every 14 days
 - 150 billable units (1,500 mg) every 21 days x 5 doses, then 150 billable units (1,500 mg) every 28 days
- SCLC: 150 billable units (1,500 mg) every 21 days x 6 doses, then 150 billable units (1,500 mg) every 28 days
- Gastric Cancer, Esophageal Cancer and Esophagogastric Junction Cancers: 150 billable units (1,500 mg) every 28 days for 3 doses

- Biliary Tract Cancers: 150 billable units (1,500 mg) every 21 days x 8 doses, then 150 billable units (1,500 mg) every 28 days
- Hepatocellular Carcinoma: 150 billable units (1,500 mg) every 28 days

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

Universal Criteria

- Patient has not received previous therapy with a programmed death (PD-1/PD-L1)-directed therapy (e.g., nivolumab, pembrolizumab, atezolizumab, avelumab, cemiplimab, dostarlimab, nivolumab/relatlimab-rmbw, retifanlimab, etc.) unless otherwise specified ^A; **AND**

Non-Small Cell Lung Cancer (NSCLC) † ‡ ^{1,3-5,16}

- Patient has unresectable stage III disease; **AND**
 - Patient has a performance status (PS) of 0-1; **AND**
 - Used as a single agent as consolidation therapy; **AND**
 - Disease has not progressed after definitive concurrent platinum-based chemoradiation; **OR**
- Patient has recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease without evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; **AND**
 - Used as first-line therapy; **AND**
 - Used for one of the following:
 - Patients with tumors that are negative for actionable molecular biomarkers* and PD-L1 ≥ 1% to 49%
 - Patients with PS of 0-1 who have tumors that are negative for actionable molecular biomarkers* and PD-L1 < 1%
 - Patients with PS of 0-1 who are positive for one of the following molecular biomarkers: EGFR exon 20, KRAS G12C, BRAF V600E, NTRK1/2/3 gene fusion, MET exon-14 skipping, RET rearrangement, or ERBB2 (HER2); **AND**
 - Used in combination with tremelimumab-actl, albumin-bound paclitaxel, and carboplatin; **OR**
 - Used in combination with tremelimumab-actl, pemetrexed, and either carboplatin or cisplatin for nonsquamous cell histology; **OR**
 - Used in combination with tremelimumab-actl, gemcitabine, and either carboplatin or cisplatin for squamous cell histology; **OR**

- Used as subsequent therapy; **AND**
 - Used for one of the following:
 - Patients with PS of 0-1 who are positive for one of the following molecular biomarkers: BRAF V600E, NTRK1/2/3 gene fusion, MET exon-14 skipping, or RET rearrangement
 - Patients with PS of 0-1 who are positive for one of the following molecular biomarkers AND received prior targeted therapy§: EGFR exon 19 deletion or exon 21 L858R tumors, EGFR S768I, L861Q, and/or G719X mutation, ALK rearrangement, or ROS1 rearrangement; **AND**
 - Used in combination with tremelimumab-actl, albumin-bound paclitaxel, and carboplatin; **OR**
 - Used in combination with tremelimumab-actl, pemetrexed, and either carboplatin or cisplatin for nonsquamous cell histology; **OR**
 - Used in combination with tremelimumab-actl, gemcitabine, and either carboplatin or cisplatin for squamous cell histology; **OR**
- Used as continuation maintenance therapy in patients who have achieved a tumor response or stable disease following initial therapy; **AND**
 - Used as a single agent following a first-line regimen with durvalumab and tremelimumab-actl plus chemotherapy; **OR**
 - Used in combination with pemetrexed following a first-line regimen with durvalumab, tremelimumab-actl, pemetrexed and either carboplatin or cisplatin for nonsquamous cell histology

** Note: Actionable molecular genomic biomarkers include EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2). If there is insufficient issue to allow testing for all of EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2) repeat biopsy and/or plasma testing should be done. If these are not feasible, treatment is guided by available results and, if unknown, these patients are treated as though they do not have driver oncogenes.*

Small Cell Lung Cancer (SCLC) † ‡ ◊^{1,3,7,8,10}

- Patient has extensive stage disease (ES-SCLC); **AND**
 - Used as first-line therapy in combination with etoposide and either carboplatin or cisplatin; **OR**
 - Used as single-agent maintenance therapy after initial therapy with etoposide and either carboplatin or cisplatin

Biliary Tract Cancers (Gallbladder Cancer or Intra-/Extra-Hepatic

Cholangiocarcinoma) † ‡ ◊^{1,3,14,18}

- Used in combination with cisplatin and gemcitabine; **AND**

- Used as primary treatment for unresectable, resected gross residual (R2), locally advanced, or metastatic disease; **OR**
- Used for recurrent disease >6 months after surgery with curative intent and >6 months after completion of adjuvant therapy

Hepatocellular Carcinoma † ‡ Φ^{1,3,11,12,15}

- Used as first-line therapy in combination with tremelimumab-actl; **AND**
 - Used for one of the following:
 - Patient has unresectable disease †
 - Patient has liver-confined disease that is inoperable by performance status, comorbidity, or with minimal or uncertain extrahepatic disease
 - Patient has metastatic disease or extensive liver tumor burden; **AND**
 - Patient has Child-Pugh class A hepatic impairment; **AND**
 - Patient has Barcelona Clinic Liver Cancer (BCLC) stage B disease that is ineligible for locoregional therapy; **OR**
 - Patient has BCLC stage C disease; **OR**
- Used as first-line therapy as a single agent; **AND**
 - Used for one of the following:
 - Patient has unresectable disease and is not a transplant candidate
 - Patient has liver-confined disease that is inoperable by performance status, comorbidity, or with minimal or uncertain extrahepatic disease
 - Patient has metastatic disease or extensive liver tumor burden; **AND**
 - Patient has Child-Pugh class A hepatic impairment; **AND**
 - Patient has Barcelona Clinic Liver Cancer (BCLC) stage B disease that is ineligible for locoregional therapy; **OR**
 - Patient has BCLC stage C disease

Esophageal Cancer and Esophagogastric Junction Cancers †^{3,19,20}

- Used as neoadjuvant therapy in combination with tremelimumab; **AND**
- Patient has microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) disease as determined by an FDA-approved or CLIA-compliant test❖; **AND**
- Patient has esophagogastric junction adenocarcinoma; **AND**
- Used as primary treatment for patients who are medically fit for surgery with cT2, N0 (high-risk lesions: lymphovascular invasion, ≥ 3cm, poorly differentiated), cT1b-cT2, N+ or cT3-cT4a, Any N disease

Gastric Cancer †^{3, 19,20}

- Used as neoadjuvant therapy in combination with tremelimumab; **AND**

- Patient has microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) disease as determined by an FDA-approved or CLIA-compliant test❖; **AND**
- Patient has adenocarcinoma; **AND**
- Used as primary treatment for potentially resectable locoregional disease (cT2 or higher, any N) in patients who are medically fit for surgery

❖ If confirmed using an FDA approved assay – <http://www.fda.gov/CompanionDiagnostic>

§ Genomic Aberration/Mutational Driver Targeted Therapies (Note: not all inclusive, refer to guidelines for appropriate use)				
Sensitizing EGFR mutation-positive tumors	ALK rearrangement-positive tumors	ROS1 rearrangement-positive tumors	BRAF V600E-mutation positive tumors	NTRK1/2/3 gene fusion positive tumors
<ul style="list-style-type: none"> – Afatinib – Erlotinib – Dacomitinib – Gefitinib – Osimertinib – Amivantamab (exon-20 insertion) 	<ul style="list-style-type: none"> – Alectinib – Brigatinib – Ceritinib – Crizotinib – Lorlatinib 	<ul style="list-style-type: none"> – Ceritinib – Crizotinib – Entrectinib – Lorlatinib 	<ul style="list-style-type: none"> – Dabrafenib ± trametinib – Encorafenib + binimetinib – Vemurafenib 	<ul style="list-style-type: none"> – Larotrectinib – Entrectinib
PD-L1 tumor expression ≥ 1%	MET exon-14 skipping mutations	RET rearrangement-positive tumors	KRAS G12C mutation positive tumors	ERBB2 (HER2) mutation positive tumors
<ul style="list-style-type: none"> – Pembrolizumab – Atezolizumab – Nivolumab + ipilimumab – Cemiplimab – Tremelimumab + durvalumab 	<ul style="list-style-type: none"> – Capmatinib – Crizotinib – Tepotinib 	<ul style="list-style-type: none"> – Selpercatinib – Cabozantinib – Pralsetinib 	<ul style="list-style-type: none"> – Sotorasib – Adagrasib 	<ul style="list-style-type: none"> – Fam-trastuzumab deruxtecan-nxki – Ado-trastuzumab emtansine

Preferred therapies and recommendations are determined by review of clinical evidence. NCCN category of recommendation is taken into account as a component of this review. Regimens deemed equally efficacious (i.e., those having the same NCCN categorization) are considered to be therapeutically equivalent.

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); ◊ Orphan Drug

IV. Renewal Criteria ^{Δ 1,3}

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe or life-threatening infusion-related reactions, immune-mediated adverse reactions (e.g.,

pneumonitis, hepatitis, colitis, endocrinopathies, nephritis with renal dysfunction, dermatology reactions, pancreatitis, etc.), complications of allogeneic hematopoietic stem cell transplantation (HCST), etc.; **AND**

NSCLC (single-agent use as consolidation therapy)

- Patient has not exceeded a maximum of 12 months of therapy

Continuation Maintenance Therapy for NSCLC

- *Refer to Section III for criteria*

Hepatocellular Carcinoma

- Cases for patients with HCC who use treatment as part of STRIDE and experience disease progression but who are clinically stable and still deriving clinical benefit will be reviewed on a case-by-case basis.

Continuation Maintenance Therapy for SCLC

- *Refer to Section III for criteria*

Esophageal Cancer and Esophagogastric Junction Cancers

- Coverage may not be renewed

Gastric Cancer

- Coverage may not be renewed

^Δ **Notes:**

- Patients responding to therapy who relapse ≥ 6 months after discontinuation due to duration are eligible to re-initiate PD-directed therapy.
- Patients previously presenting with aggressive disease who are exhibiting stable disease on treatment as their best response (or if therapy improved performance status) may be eligible for continued therapy without interruption or discontinuation.
- Patients who complete adjuvant therapy and progress ≥ 6 months after discontinuation are eligible to re-initiate PD-directed therapy for metastatic disease.
- Patients whose tumors, upon re-biopsy, demonstrate a change in actionable mutation (e.g., MSS initial biopsy; MSI-H subsequent biopsy) may be eligible to re-initiate PD-directed therapy and will be evaluated on a case-by-case basis.

V. Dosage/Administration ^{Δ 1,7,8,12,17,18,20}

Indication	Dose
------------	------

<p>Non-Small Cell Lung Cancer (NSCLC)</p>	<p><u>Single agent:</u></p> <ul style="list-style-type: none"> • Weight ≥ 30 kg: Administer 10 mg/kg intravenously every 14 days OR 1,500 mg intravenously every 28 days until disease progression or unacceptable toxicity • Weight < 30 kg: Administer 10 mg/kg intravenously every 14 days until disease progression or unacceptable toxicity • NOTE: Use as consolidation therapy for unresectable stage III disease may continue up to a maximum of 12 months in patients without disease progression or unacceptable toxicity. <p><u>In combination with Tremelimumab-actl* and Platinum-Based Chemotherapy§:</u></p> <ul style="list-style-type: none"> • Weight ≥ 30 kg: Administer 1,500 mg intravenously every 21 days x 5 cycles, followed by a maintenance dose of 1,500 mg every 28 days thereafter, until disease progression or unacceptable toxicity • Weight < 30 kg: Administer 20 mg/kg intravenously every 21 days x 5 cycles, followed by a maintenance dose of 20 mg/kg every 28 days thereafter, until disease progression or unacceptable toxicity <p>*Note: Refer to the Prescribing Information for tremelimumab-actl dosing information</p> <p>§ If patients receive fewer than 4 cycles of platinum-based chemotherapy, the remaining cycles of tremelimumab-actl (up to a total of 5) should be given after the platinum-based chemotherapy phase, in combination with durvalumab, every 4 weeks.</p>
<p>Small Cell Lung Cancer (SCLC)</p>	<p><u>Weight ≥ 30 kg:</u></p> <p>Administer 1,500 mg intravenously in combination with chemotherapy every 21 days x 4 cycles*, followed by a maintenance dose of 1,500 mg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</p> <p><u>Weight < 30 kg:</u></p> <p>Administer 20 mg/kg intravenously in combination with chemotherapy every 21 days x 4 cycles*, followed by a maintenance dose of 10 mg/kg as a single agent every 14 days thereafter, until disease progression or unacceptable toxicity</p> <p>*Note: Patients may receive up to 2 additional cycles in combination with chemotherapy based on response and tolerability after the initial 4 cycles (6 cycles of combination therapy in total) ⁸</p>
<p>Hepatocellular Carcinoma</p>	<p><u>Single agent:</u></p> <p>Administer 1,500 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</p> <p><u>STRIDE (Single Tremelimumab Regular Interval Durvalumab):</u></p> <ul style="list-style-type: none"> • Weight ≥ 30 kg: Administer 1,500 mg intravenously following a single dose of tremelimumab-actl* at Day 1 of Cycle 1, followed by a maintenance dose of 1,500 mg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity • Weight < 30 kg: Administer 20 mg/kg intravenously following a single dose of tremelimumab-actl* at Day 1 of Cycle 1, followed by a maintenance dose of 20 mg/kg

	<p>as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</p> <p>*Note: Refer to the Prescribing Information for tremelimumab-actl dosing information</p>
Biliary Tract Cancers	<p><u>Weight ≥30 kg:</u></p> <p>Administer 1,500 mg intravenously in combination with chemotherapy every 21 days for up to 8 cycles, followed by a maintenance dose of 1,500 mg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</p> <p><u>Weight <30 kg:</u></p> <p>Administer 20 mg/kg intravenously in combination with chemotherapy every 21 days for up to 8 cycles, followed by a maintenance dose of 20 mg/kg as a single agent every 28 days thereafter, until disease progression or unacceptable toxicity</p>
Gastric Cancer, Esophageal Cancer and Esophagogastric Junction Cancers	Administer 1,500 mg intravenously every 28 days for 3 cycles preoperatively
<p><u>Dosing should be calculated using actual body weight and not flat dosing (as applicable) based on the following:</u></p> <ul style="list-style-type: none"> • Patient weight > 30 kg and <75 kg: Use 20 mg/kg dosing <p><i>Note: This information is not meant to replace clinical decision making when initiating or modifying medication therapy and should only be used as a guide. Patient-specific variables should be taken into account.</i></p>	

VI. Billing Code/Availability Information

HCPCS Code:

- J9173 – Injection, durvalumab, 10 mg; 1 billable unit = 10 mg

NDC(s):

- Imfinzi 120 mg/2.4 mL single-dose vial: 00310-4500-xx
- Imfinzi 500 mg/10 mL single-dose vial: 00310-4611-xx

VII. References (STANDARD)

1. Imfinzi [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; June 2023. Accessed December 2023.
2. Massard C, Gordon MS, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. *J Clin Oncol*. 2016 Sep 10;34(26):3119-25.
3. Referenced with permission from the NCCN Drugs and Biologics Compendium (NCCN Compendium®) durvalumab. National Comprehensive Cancer Network, 2023. The NCCN

Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed December 2023.

4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *N Engl J Med*. 2017 Sep 8.
5. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Non-Small Cell Lung Cancer. Version 5.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed December 2023.
6. Gupta S, Sonpavde G, Grivas P, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). *J Clin Oncol*. 2019 Mar 1;37(7_suppl):451.
7. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
8. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Small Cell Lung Cancer. Version 2.2024. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed December 2023.
9. Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. *JAMA Oncol*. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.
10. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8.
11. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Hepatocellular Carcinoma. Version 2.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most

recent and complete version of the Compendium, go online to NCCN.org. Accessed December 2023.

12. Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. *Journal of Clinical Oncology* 2022 40:4_suppl, 379-379.
13. Govindan R, Aggarwal C, Antonia SJ, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. *Journal for ImmunoTherapy of Cancer* 2022;10:e003956. Doi: 10.1136/jitc-2021-003956.
14. Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. *J Clin Oncol*. 2022 Feb 1;40(4_suppl):378-378.
15. Abou-Alfa GK, Chan SL, Furuse J, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. *Journal of Clinical Oncology* 36, no. 15_suppl. DOI: 10.1200/JCO.2018.36.15_suppl.TPS4144.
16. Johnson ML, Cho BC, Luft A, et al; POSEIDON investigators. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. *J Clin Oncol*. 2022 Nov 3;JCO2200975. doi: 10.1200/JCO.22.00975.
17. Paz-Ares L, Dvorkin M, Chen Y, et al; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6.
18. Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. *NEJM Evidence* 2022; 1:EVIDo2200015. Available at <https://doi.org/10.1056/EVIDo2200015>.
19. Kelly R, Lee J, Bang Y, et al. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. *Clin Cancer Res*. 2020 Feb 15;26(4):846-854. doi: 10.1158/1078-0432.CCR-19-2443. Epub 2019 Nov 1. PMID: 31676670; PMCID: PMC7748730. 2020 Feb 15;26(4):846-854. doi: 10.1158/1078-0432.CCR-19-2443. Epub 2019 Nov 1.
20. Raimondi A, Palermo F, Prisciandaro M, et al. Tremellmumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. *Cancers (Basel)*. 2021 Jun 7;13(11):2839. doi: 10.3390/cancers13112839. PMID: 34200267; PMCID: PMC8201030.

VIII. References (ENHANCED)

- 1e. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N Engl J Med*. 2017;376(11):1015–1026.
- 2e. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet*. 2016;387(10031):1909–1920.
- 3e. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2018 Feb 24;391(10122):748-757.
- 4e. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2017 Mar;18(3):312-322.
- 5e. Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncol*. 2018 Jan;19(1):51-64.
- 6e. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N Engl J Med*. 2018 Dec 13;379(24):2342-2350.
- 7e. Horn L, Mansfield AS, Szczesna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2018 Dec 6;379(23):2220-2229.
- 8e. Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med*. 2019 Jul 25;381(4):338-348.
- 9e. Llovet JM, Ricci S, Mazzaferro et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008 Jul 24;359(4):378-90.
- 10e. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*. 2018 Mar 24;391(10126):1163-1173.
- 11e. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med*. 2020 May 14;382(20):1894-1905.
- 12e. Gogishvili M, Melkadze T, Makharadze T, et al. LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). *Annals of Oncology*, ISSN: 0923-7534, Vol: 32, SUPPLEMENT 5, S1328, SEPTEMBER 01, 2021. DOI10.1016/j.annonc.2021.08.2130.
- 13e. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018 Nov 22;379(21):2040-2051.

- 14e. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. *NEJM Evid* 2022;1:EVIDo2100070.
- 15e. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010;362:1273-1281.
- 16e. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med*. 2013 Oct 31;369(18):1691-703.
- 17e. Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. *J Clin Oncol* 2023;41:2181-2190.
- 18e. André T, Tougeron D, Piessen G, et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. *J Clin Oncol*. 2023 Jan 10;41(2):255-265.
- 19e. Pietrantonio F, Raimondi A, Lonardi S, et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/ GEJAC). *Journal of Clinical Oncology* 2023;41:358-358
- 20e. Magellan Rx Management. Imfinzi Clinical Literature Review Analysis. Last updated December 2023. Accessed December 2023.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.8	Malignant neoplasm of overlapping sites of esophagus
C15.9	Malignant neoplasm of esophagus, unspecified
C16.0	Malignant neoplasm of cardia
C16.1	Malignant neoplasm of fundus of stomach
C16.2	Malignant neoplasm of body of stomach
C16.3	Malignant neoplasm of pyloric antrum
C16.4	Malignant neoplasm of pylorus
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C16.8	Malignant neoplasm of overlapping sites of stomach
C16.9	Malignant neoplasm of stomach, unspecified
C22.0	Liver cell carcinoma
C22.1	Intrahepatic bile duct carcinoma
C22.8	Malignant neoplasm of liver, primary, unspecified as to type

ICD-10	ICD-10 Description
C22.9	Malignant neoplasm of liver, not specified as primary or secondary
C23	Malignant neoplasm of gallbladder
C24.0	Malignant neoplasm of other and unspecified parts of biliary tract
C24.8	Malignant neoplasm of overlapping sites of biliary tract
C24.9	Malignant neoplasm of biliary tract, unspecified
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C7A.1	Malignant poorly differentiated neuroendocrine tumors
D37.1	Neoplasm of uncertain behavior of stomach
D37.8	Neoplasm of uncertain behavior of other specified digestive organs
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified
Z85.00	Personal history of malignant neoplasm of unspecified digestive organ
Z85.01	Personal history of malignant neoplasm of esophagus
Z85.118	Personal history of other malignant neoplasm of bronchus and lung

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local

Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC